Addressing Racial Disparities in Health Care
Latest News
The Different Phases Of Chronic Myeloid Leukemia & Their Management
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic myeloid leukemia (CML) is a type of blood cancer that is broken up into several different phases. The treatment options available to you will depend on the phase, as well as several other factors. The myeloid tissue, called the bone marrow, is the red spongy […]
Learn MoreThe Different Types of Myeloproliferative Neoplasms (MPN)
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic myeloid leukemia (CML) is a type of blood cancer known as a myeloproliferative neoplasm (MPNs). There are several different types of blood cancer that fall under the MPN umbrella. These diseases are characterized by an over-proliferation of one of the components in the bone marrow. […]
Learn MoreTyrosine Kinase Inhibitor (TKI) Therapy for Chronic Myeloid Leukemia (CML)
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Tyrosine Kinase Inhibitors (TKIs) are a highly specific treatment for Chronic Myeloid Leukemia (CML). CML is a type of blood cancer that arises in the cells of the bone marrow. TKIs are targeted therapies, which can exploit the unique features of cancer cells and weaponize them […]
Learn MoreNewly FDA-Approved Drug Elahere May Be Effective Treatment For Patients With A Particularly Aggressive Form Of Ovarian Cancer
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Ovarian cancer cells commonly carry folate receptor alpha (FRα) protein on their surface. Up to 80% of new and recurrent ovarian cancers may carry this protein. Generally, FRα levels tend to be high in more aggressive ovarian cancers. Oncologists can order FRα testing for their […]
Learn MoreNew Combination Of Immunotherapy And Chemotherapy Could Effectively Treat Metastatic Bladder Cancer
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. A new immunotherapy and chemotherapy combination may be an effective treatment for patients with metastatic bladder cancers who cannot receive cisplatin. Patients who cannot receive cisplatin for their cancer have historically fared very poorly. In a study, the new treatment achieved a response in 64.5% […]
Learn MoreImmunotherapy Drug Keytruda Shows Promising Event-Free Survival Results For High-Risk Melanoma Patients When Used Before And After Surgery
Contributed by Dr. James Taylor, MD, MPH, a Medical Fellow at SurvivorNet. A new study of patients with high-risk melanoma shows using the immunotherapy agent pembrolizumab, also known as Keytruda, used before and after surgery reduces the risk of tumor recurrence. Immunotherapy given before surgery can help prime the immune system to fight off cancer […]
Learn More‘Practice Changing’ Trial Results Suggest Tagrisso Can Delay Recurrence of EGFR Mutated Lung Cancer
Contributed by Abigail Seaberg, writer at SurvivorNet. The drug Tagrisso is showing promise for lung cancer patients, yet again. Updated results from the phase III ADAURA study presented at the European Society for Medical Oncology (ESMO) Congress 2022 showed that AstraZeneca’s drug osimertinib, brand name Tagrisso, demonstrated more exciting results for lung cancer patients […]
Learn MoreDrug Enhertu Targets New Category of Her2-Low Metastatic Breast Cancer Patients
Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. For oncologists across the country, including community practices, the new developments around categorizing breast cancer patients as HER2-low is starting to play out in practice. The drug enhertu was approved for patients previously considered HER2 negative, but in an important breakthrough, the drug has been approved by […]
Learn More